Investment Banking
Dedicated Leadership in Life Sciences M&A
August 03, 2023
Oppenheimer’s Healthcare Investment Banking Group Closes Four Life Sciences M&A Transactions in 2023 Year-to-Date.
Fresh off a robust first half of 2023, life sciences M&A activity continues to build strong momentum in both deal value and volume. Oppenheimer’s Healthcare Life Sciences Team continues its leading efforts in advising biopharma companies by closing four life sciences transactions this year. For more information, please contact Michael Margolis, Don Ritucci, or Stefan Loren.
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Co-Head of Healthcare, Head of Healthcare Life Sciences
Name:
Don Ritucci
Title:Managing Director, Head of Healthcare M&A
Name:
Stefan Loren, Ph.D.
Title:Managing Director, Healthcare Life Sciences
DISCLOSURES
This document is for discussion purposes only and does not constitute advice of any kind, including tax, accounting, legal or regulatory advice, and Oppenheimer & co. Inc. Is not and does not hold itself out to be an advisor as to tax, accounting, legal or regulatory matters.
The information contained herein was obtained from public sources and was relied upon by Oppenheimer & co. Inc. Without assuming responsibility for independent verification as to the accuracy or completeness of such information. No representation or warranty, express or implied, is made as to the accuracy or completeness of such information and nothing contained herein is, or shall be relied upon as, a representation or warranty, whether as to the past or the future.
Oppenheimer & co. Inc. assumes no obligation to update or otherwise revise these materials.
Oppenheimer & co. Inc.’s research department is required to be independent from its investment banking department, and its research analysts may hold and make statements or investment recommendations that differ from the views of its investment bankers. Further, pursuant to applicable law, Oppenheimer & co. Inc. Is (among other things) precluded from offering favorable research, a specific rating or a specific price target, or threaten to change research, a rating or a price target, as consideration or inducement for the receipt of business or compensation.
Oppenheimer & co. Inc. Transacts business on all principal exchanges and member SIPC. 5853986.1